azelastine hydrochloride
Vividrin contains the active substance azelastine hydrochloride, which belongs to a group of medicines called antiallergics (antihistamines). Antihistamines prevent the effects of substances such as histamine, which the body produces as part of an allergic reaction. Azelastine has been shown to reduce ocular inflammation.
This medicine can be used for the treatment and prevention of ocular disorders caused by hay fever (seasonal allergic conjunctivitis, which manifests with redness, itching of the eyes or tearing) in adults and children from 4 years of age.
Vividrin can be used for ocular disorders caused by allergy to dust mites or animal hair (perennial allergic conjunctivitis) in adults and children from 12 years of age.
This medicine is a preservative-free solution.
Do not use Vividrin:
Warnings and precautions
Consult your doctor or pharmacist before starting to use this medicine:
This medicine is not intended for the treatment of eye infections.
Children and adolescents
For the treatment of ocular disorders caused by hay fever (seasonal allergic conjunctivitis):
Do not give this medicine to children under 4 years of age, as its safety and efficacy have not been established.
For the treatment of ocular disorders caused by allergy (perennial allergic conjunctivitis):
Do not give this medicine to children under 12 years of age, as its safety and efficacy have not been established.
Other medicines and Vividrin
Although it is not known if Vividrin can be affected by other medicines, inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medicine.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
You may experience blurred vision for a short time when using Vividrin. If this happens, wait until your vision is clear before driving or using machinery.
Remove your contact lenses before applying the eye drops and wait at least 15 minutes before putting them back in.
Follow the instructions for administration of this medicine exactly as indicated by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist.
When you are about to use these eye drops, wash your hands well before opening the container and follow these steps:
| |
| |
| |
If you are unable to instill the product, repeat steps A2 and B1 | |
Gently pull the lower eyelid down while looking up, place the container over the eye, and press gradually on the center of the container until the drop falls. Avoid the tip of the container coming into contact with the eye and eyelids. | |
With the eye still closed, clean up any excess. To reduce possible systemic absorption, it is recommended to press with your finger on the inner corner of the eye for 2 minutes after each instillation while keeping the eye closed. | |
| |
To eliminate residual drops:
| |
| |
|
Like all medicines, this medicine can cause side effects, although not everybody gets them.
These effects include:
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet.
You can also report side effects directly to the Spanish Medicines Agency's Pharmacovigilance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date is the last day of the month stated.
Do not store above 25°C.
Do not freeze.
After opening:Do not use this medicine if the bottle was opened more than 3 months ago. This medicine should not be stored above 25°C.
Medicines should not be disposed of via wastewater or household waste. Return the containers and any unused medicines to a pharmacy for disposal. This will help protect the environment.
Composition of Vividrin
Each milliliter contains 0.5 mg/ml of azelastine hydrochloride. Each drop contains 0.0216 mg of azelastine hydrochloride.
The other ingredients are sorbitol, hypromellose, disodium edetate, sodium hydroxide, and purified water.
Appearance of the product and contents of the pack
Vividrin is a clear solution.
Vividrin is presented in a plastic bottle with a dispenser system and a cap. One bottle contains 10 ml of solution.
Marketing authorisation holder and manufacturer
Marketing authorisation holder
Bausch + Lomb Ireland Limited
3013 Lake Drive
Citywest Business Campus
Dublin 24, D24PPT3
Ireland
Manufacturer
Laboratoire Chauvin
Zone Industrielle De Ripotier
50 Avenue Jean Monnet
07200 Aubenas
France
You can obtain further information on this medicine by contacting the local representative of the marketing authorisation holder:
Bausch & Lomb S.A.
Avda. Valdelaparra, nº 4
28108 Alcobendas
Madrid, Spain.
Tel: 91 – 657 63 00
This medicine is authorised in the Member States of the EEA under the following names
Germany: Vividrin Azelastin MDO 0,5 mg/ml Augentropfen, Lösung
Austria: Vividrin Azelastin MDO 0,5 mg/ml Augentropfen, Lösung
Czech Republic: Ocuazel
Spain: Vividrin 0,5 mg/ml colirio en solución
Croatia: Vivialle 0,5 mg/ml kapi za oko, otopina
Hungary: Vivialle 0,5 mg/ml oldatos szemcsepp
Italy: Vividrin occhi 0,5 mg/ml collirio, soluzione
Poland: Azel-Drop Free
Portugal: Vivilin, 0.5 mg/ml Colírio, Solução
Slovakia: Ocuazel
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).